Novartis: Just What The Doctor Ordered

The pharmaceutical company's pipeline remains robust, which could translate into decent core EPS growth prospects.Since last October, Novartis' shares have lagged the S&P 500 index.This article was coproduced with Kody Kester.Introducing iREIT®Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.We recently ...